Comparison of the efficacy between the domestic immune checkpoint inhibitor group and the imported immune checkpoint inhibitor group
There were 65 patients receiving immunotherapy in this study, all of whom received PD-1 immune checkpoint inhibitors. Among them, there were 13 patients treated with imported immune checkpoint inhibitors, all of which were pembrolizumab, and 52 patients treated with domestic immune checkpoint inhibitors, which were sintilimab and tislelizumab. The results showed that among the 52 patients treated with domestic immune checkpoint inhibitors, 17 patients with PD, 32 patients with SD, 3 patients with PR, 3 patients met the criteria for objective response, and 35 patients met the criteria for for disease control, while among the 13 patients treated with imported immune checkpoint inhibitors, 4 patients with PD, 8 patients with SD, 1 patient with PR, 1 patient met the criteria for objective response, and 9 patients met the criteria for disease control. The results of the different evaluations of the two groups of patients were statistically analysed separately, and the results using the Chi-square test and Fisher’s exact test were as follows: in the case of PD or not, there was no statistical difference between the two groups, P =0.894; in the case of SD or not, there was no statistical difference between the two groups,P >0.999; in the case of PR or not, there was no statistical difference between the two groups, P =0.796; in the case of objective response or not, there is no statistical difference between the two groups, P =0.796; in the case of disease control or not, there is no statistical difference between the two groups,P =0.894, as shown in Table 3. Overall, for patients with treated metastatic colorectal cancer, there was no difference in the efficacy of either domestic or imported immune checkpoint inhibitors for treatment.
Table 3 Comparison of efficacy between the domestic ICI group and the imported ICI group